Detalles de la búsqueda
1.
Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.
Clin Exp Rheumatol
; 34(3): 489-99, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26966919
2.
Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.
BMC Musculoskelet Disord
; 16: 176, 2015 Jul 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-26228643
3.
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.
BMC Musculoskelet Disord
; 15: 14, 2014 Jan 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-24410774
4.
Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective.
Clin Exp Rheumatol
; 36(5): 935-936, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29600933
5.
Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study.
RMD Open
; 3(1): e000345, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28243468
6.
Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.
RMD Open
; 3(2): e000538, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29435360
7.
The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.
Joint Bone Spine
; 84(5): 571-576, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28043761
Resultados
1 -
7
de 7
1
Próxima >
>>